瑞舒伐他汀联合双环醇片通过抗纤维化机制治疗非酒精性脂肪性肝炎的研究

doi:10.3969/j.issn.10073205.2019.04.008

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨瑞舒伐他汀联合双环醇片治疗非酒精性脂肪性肝炎（nonalcoholic steatohepatitis，NASH）的临床效果和作用机制。
〖HTH〗方法〖HTSS〗〖KG*2〗将120例NASH患者随机分为单纯瑞舒伐他汀治疗组（R组）和瑞舒伐他汀联合双环醇片治疗组（R+D组），每组60例。比较2组治疗前后血清肝功能、血脂、肝纤维化指标和肝穿刺组织肝纤维化相关指标。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗后，2组丙氨酸转氨酶（glutamic pyruvic transaminase，ALT）、天冬氨酸转氨酶（glutamic oxaloacetic transaminase,AST）和谷氨酰转移酶（glutamyl transpeptadase,GGT）水平均明显低于治疗前，R+D组ALT、AST和GGT水平均明显低于R组，差异有统计学意义（P＜005）。2组总胆固醇（total cholesterol,TC）、三酰甘油（triglyceride,TG）和低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDLC）水平均明显低于治疗前，高密度脂蛋白胆固醇（high density lipoprotein cholesterol，HDLC）明显高于治疗前，差异有统计学意义（P＜005）；2组TC、TG、HDLC和LDLC水平差异均无统计学意义（P＞005）。R+D组透明质酸（haluronic acid，HA）、层黏蛋白（laminin,LN）、Ⅲ型前胶原肽（procollagen Ⅲ，PCⅢ）和Ⅳ型胶原（collagen Ⅳ，CⅣ）水平均明显低于治疗前，R+D组HA、LN、PCⅢ和CⅣ均明显低于R组，差异有统计学意义（P＜005）。R+D组肝脏胶原Ⅰ、胶原Ⅳ和纤维黏连蛋白mRNA和蛋白表达均明显低于治疗前，R+D组肝脏胶原Ⅰ、胶原Ⅳ和纤维黏连蛋白mRNA和蛋白的表达均明显低于R组，差异有统计学意义（P＜005）。
〖HTH〗结论〖HTSS〗〖KG*2〗瑞舒伐他汀联合双环醇片治疗NASH患者的肝功能和肝纤维化指标显著改善，其疗效优于单纯瑞舒伐他汀治疗。

关键词: 脂肪肝, 非酒精性脂肪性肝炎, 瑞舒伐他汀, 双环醇片

Abstract: ［Abstract］〓Objective〖HTSS〗〓To explore the clinical efficacy and mechanism of rosuvastatin combined with bicyclol tablets on nonalcoholic steatohepatitis(NASH).
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 120 NASH patients were randomly divided into the rosuvastatin treatment group and the rosuvastatin combined with bicyclol tablets, 60 patients in each group. The changes of serum liver function, blood lipid and liver fibrosis index as well as liver tissues fibrosis related index were observed before and after treatment in the two groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After treatment, the glutamic pyruvic transaminase(ALT), glutamyl transpeptadase(AST) and glutamyl transpeptadase(GGT) levels of the two groups were significantly lower than that before treatment, and the ALT, AST and GGT levels of the R+D group were significantly lower than those of the R group, with statistically significant differences(P＜005). After treatment, 2 groups of total cholesterol(TC), triglyceride(TG) and low density lipoprotein cholesterol(LDLC) level was lower than that before treatment, high density lipoprotein cholesterol(HDLC) were significantly higher than those before treatment, the difference was statistically significant(P＜005). There was no significant difference in TC, TG, HDLC and LDLC levels between the two groups after treatment(P＞005). Hyaluronic acid(HA), laminin(LN), procollagen Ⅲ(PCⅢ) and collagen Ⅳ(CⅣ) level of R+D groups was lower than that before treatment, HA, LN, PCⅢ and CⅣof R+D group was lower than that in R group, the difference was statistically significant(P＜005). The mRNA and protein expressions of collagen Ⅰ, collagen Ⅳ and fibronectin in the liver of R+D group were significantly lower than those before treatment, and the mRNA and protein expressions of collagen Ⅰ, collagen Ⅳ and fibronectin in the liver of R+D group were significantly lower than those of the R group, with statistically significant differences(P＜005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The indexes of liver function and liver fibrosis in NASH patients were significantly improved after the combined treatment of rosuvastatin and bicyclol tablets, and the curative effects were superior to that of rosuvastatin alone.

Key words: fatty liver, nonalcoholic steatohepatitis, rosuvastatin;bicyclol tablets

任瑞华，王〓钧，雷建华，梁〓静. 瑞舒伐他汀联合双环醇片通过抗纤维化机制治疗非酒精性脂肪性肝炎的研究[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2019.04.008.

REN Ruihua， WANG Jun， LEI Jianhua， LIANG Jing. Study of rosuvastatin combined with bicyclol tablets in the treatment of nonalcoholic steatohepatitis through antifibrosis mechanism[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2019.04.008.

[1]	李海玲, 董陆玲, 杨秀红, 张贵山. 糖尿病合并MAFLD患者外周血Chemerin与糖脂代谢、内脏脂肪、氧化应激及炎症指标的关系[J]. 河北医科大学学报, 2022, 43(3): 275-279，294.
[2]	龙小雪, 李鹏, 栗雯霏, 吴珊珊, 栗建辉, 申文增. 应用化疗药及内分泌药后兔肝的超声表现及病理改变的对照研究[J]. 河北医科大学学报, 2020, 41(7): 773-779.
[3]	张彦敏1，高〓冕1，董俊婵2，王志先3，牛晓芬1，王〓力1*. 铁路职工体检脂肪肝影响因素分析#br#[J]. 河北医科大学学报, 2019, 40(7): 859-862.
[4]	刘荣红1，李国强2，赵文增3，徐娅丽2，刘〓燕1，陈喜珊1. 人体成分分析仪在成年人正常体重人群脂肪肝中的应用[J]. 河北医科大学学报, 2019, 40(6): 723-726.
[5]	陈〓梅1，郭明升2*，武〓华3，刘〓娟2. 阿托伐他汀和瑞舒伐他汀对非糖尿病脑梗死二级预防患者血糖的影响[J]. 河北医科大学学报, 2019, 40(1): 16-19,24.
[6]	魏文志，温晓华，刘艳如，高〓冕，田京利. 体检人群非酒精性脂肪性肝病与高尿酸血症及脂代谢紊乱的关系[J]. 河北医科大学学报, 2018, 38(8): 894-897,902.
[7]	谈力欣1，刘〓焱2，张秀云3，檀力静4，焦〓骞5* . 2型糖尿病并发非酒精性脂肪肝患者生化指标、胰岛功能和周围神经功能的临床研究[J]. 河北医科大学学报, 2018, 38(7): 773-778.
[8]	刘爱宁1，杨文刚1，鞠树红1，孙一鸣1，马〓骏2，周〓晖3*. 叶酸及不同剂量瑞舒伐他汀对HHcy小鼠动脉粥样硬化相关基因表达的影响[J]. 河北医科大学学报, 2018, 38(4): 378-382.
[9]	梁炬峰，齐韵然，姚玉环，高〓强，张泽琛*. 非酒精性脂肪性肝病人群知晓率及发病危险因素研究#br#[J]. 河北医科大学学报, 2018, 39(2): 210-214.
[10]	王艳林1，张〓旭1，闫亚飞1，栗建辉2*. 常规超声及声辐射力脉冲成像检测化疗药物肝损害的实验研究[J]. 河北医科大学学报, 2017, 37(5): 579-584.
[11]	卢彩平1，赵晓建2，曹俊娟3，苏白玉1，吴〓琳4，任巧华1. 抗氧化降脂治疗对非酒精性脂肪肝大鼠的影响[J]. 河北医科大学学报, 2016, 37(8): 883-888.
[12]	刘红芬1，范亚坤2，张淑梅1，常丽丽1. 强肝胶囊治疗单纯性肥胖脂肪肝患者临床疗效及瘦素的变化特征[J]. 河北医科大学学报, 2016, 37(11): 1257-1259,1269.
[13]	赵岩;张月娥;黄一茜;朱晓娟;张倩;陈妹红. 阿托伐他汀治疗非酒精性脂肪肝患者的血管结构与功能的超声评价[J]. , 2015, 36(8): 975-975.
[14]	张磊;颜伟;闫晓婧. 7379例体检人员脂肪肝患病率及危险因素分析[J]. , 2015, 36(6): 731-731.
[15]	曾静波;庄晓明;穆君. 二甲双胍联合吡格列酮对初发2型糖尿病并发非酒精性脂肪肝的疗效及对血清Vaspin水平的影响[J]. , 2015, 36(5): 509-509.

瑞舒伐他汀联合双环醇片通过抗纤维化机制治疗非酒精性脂肪性肝炎的研究

Study of rosuvastatin combined with bicyclol tablets in the treatment of nonalcoholic steatohepatitis through antifibrosis mechanism

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价